New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

A retrospective study led by Northwestern Medicine investigators found that the chimeric antigen receptor (CAR) T-cell immunotherapy drug tisagenlecleucel demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-cell ALL), even when the drug doesn’t meet the FDA’s strict manufacturing standards.

The findings, published in Blood, may help widen therapeutic interventions for these patients who have otherwise exhausted all other treatment options, according to Jenna Rossoff, MD, instructor of Pediatrics in the Division of Hematology, Oncology and Stem Cell Transplantation and lead author of the study.

“I hope that these findings will make clinicians feel more comfortable with giving a slightly out-of-spec product to their patients, especially when they’re otherwise in a tight spot without other therapeutic options or ones with a very high toxicity profile,” said Rossoff, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

B-cell ALL, the most common type of cancer in children, is a type of blood and bone marrow cancer that develops in early forms of B-cells β€” white blood cells β€” and progresses quickly if left untreated. With the advancement of treatment, including chemotherapy, immunotherapy and radiation therapy, the five-year survival rate for pediatric patients with B-cell ALL has increased to 90 percent.

CAR T-cell therapy, a type of immunotherapy that utilizes a patient’s healthy T-cells that are collected through a process called leukapheresis and reengineered to attack cancer cells, has been shown to be especially effective for patients who have relapsed or are unresponsive to standard treatments.

A recent clinical trial found that pediatric patients with relapsed or high-risk B-cell ALL who received the CAR T-cell therapy drug tisagenlecleucel demonstrated a remission rate of 81 percent three months after infusion. Specifically, tisagenlecleucel utilizes a patient’s healthy T-cells that are reengineered to fight off the protein CD19 on the surface on B-cell ALL cancer cells.

While results from that clinical trial prompted the drug’s FDA approval in 2017, some of the FDA’s safety and efficacy specifications may be more stringent than necessary, according to the authors. Because of these criteria, some tisagenlecleucel is manufactured that fails to meet certain release criteria and is deemed ineligible for commercial release, or “out-of-specification.”

If a product is deemed out-of-specification, physicians can still decide to use the product, assuming there are no safety concerns. However, until now there has been little published data regarding clinical outcomes in patients with B-cell ALL who’ve received out-of-specification products, according to Rossoff.

In the current study, Rossoff and colleagues analyzed retrospective data from 185 pediatric patients diagnosed with relapsed or refractory B-ALL who received out-of-specification tisagenlecleucel or standard-of-care tisagenlecleucel at 15 pediatric clinical sites across the United States.

Overall, the investigators found that survival rates and toxicity profiles between both groups were similar, demonstrating the drug’s overall safety and efficacy.

In the future, Rossoff said more prospective studies performed in different clinical contexts are needed to create specific cut-off points that can help physicians more accurately determine which patients are will benefit from the therapy.

My goal is to continue to gather data from patients who are treated with this therapy so that we can better define critical cutoffs outside of which products are less likely to be safe or effective.”

Jenna Rossoff, MD, Lead Author

Source:

Journal reference:

Rossoff, J., et al. (2021) Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia. Blood. doi.org/10.1182/blood.2021012392.

Baby News

Related Posts

Streusel Topped Healthy Banana Bread

Comments Off on Streusel Topped Healthy Banana Bread

Creamy Blueberry Popsicles – Super Healthy Kids

Comments Off on Creamy Blueberry Popsicles – Super Healthy Kids

Exposure to multiple phthalates during pregnancy increases risk of preterm birth

Comments Off on Exposure to multiple phthalates during pregnancy increases risk of preterm birth

Longer breastfeeding duration associated with improved cognitive scores in children

Comments Off on Longer breastfeeding duration associated with improved cognitive scores in children

Attending daycare may increase lung complications in preterm children with bronchopulmonary dysplasia

Comments Off on Attending daycare may increase lung complications in preterm children with bronchopulmonary dysplasia

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

Comments Off on SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

Pinto Bean Casserole (Easy Mexican Recipe)

Comments Off on Pinto Bean Casserole (Easy Mexican Recipe)

Do traumatic brain injuries in pregnant mothers impact fetal development?

Comments Off on Do traumatic brain injuries in pregnant mothers impact fetal development?

Sharing of children’s photos on social media is linked with permissive, confident parenting styles

Comments Off on Sharing of children’s photos on social media is linked with permissive, confident parenting styles

Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

Comments Off on Reduced neutralization against Omicron variant in fully immunized adolescents with BNT162b2 vaccine

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Comments Off on SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Extra caution needed while screening depressed teenagers with Type 1 diabetes

Comments Off on Extra caution needed while screening depressed teenagers with Type 1 diabetes

Create Account



Log In Your Account